180 Life Sciences Corporate Media Kit

14 Phase 2a Completed: 40 mg (in 0.4ml) Adalimumab is Effective • Dose ranging with 28 patients. • 40 mg in 0.4ml - effective dose. • Funded by HICF (Wellcome Trust + Dept of Health) and 180 Life Sciences Trial Overview Adalimumab injected directly into the nodule Demonstrated efficacy at high concentration & dose 15mg in 0.3ml (1.60 ± 0.67) 40mg in 0.4ml Placebo (1.51 ± 0.65) 35mg in 0.7ml* (1.44 ± 0.48) (1.09 ± 0.89) *Leakage observed from site injection due to large volume 5.0 4.0 3.0 2.0 1.0 0.0 Placebo 15mg 35mg 40mg adalimumab Treatment p=0.024 p=0.006 p<0.001 1250 1000 750 500 250 0.0 Placebo 15mg 35mg 40mg adalimumab p=0.019 The First Trial Of Any Targeted Therapy In Early DD (1) : Anti-Tumour Necrosis Factor Therapy for Dupuytren’s Disease: A Randomized Dose Response Proof of Concept Phase 2A Clinical Trial (2) (1) Approval only from MHRA/CCMO and relevant accredited ethics committees. (2) EBioMedicine 33 (2018) 282-288 180 Life Sciences Corp. www.180lifesciences.com Q4 2020